FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL® as a Nerve Block for Regional Analgesia

Go back to FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL® as a Nerve Block for Regional Analgesia

Pacira Pharma (PCRX) Confims Trading Halt Ahead of FDA AdCom

February 14, 2018 1:29 PM EST

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that NASDAQ has halted trading of the companys common stock.

The U.S. Food and Drug Administrations (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting to review the companys supplemental New Drug Application seeking approval of EXPAREL®... More